Prostatilen Research for Benign Prostatic Hyperplasia (BPH)
An evidence-based overview of research examining Prostatilen in the context of benign prostatic hyperplasia (bph). This page synthesizes findings from peer-reviewed literature.
Research Summary
Russian clinical studies report improvements in IPSS scores, peak flow rates, and quality of life measures in BPH patients. Prostatilen is sometimes used as adjunct therapy to standard BPH medications in Russia. Evidence quality is low with no placebo-controlled Western trials.
Referenced Studies
Click any PMID to view the full study on PubMed.
Other Peptides Studied for Benign Prostatic Hyperplasia (BPH)
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Prostatilen may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.